Novo Nordisk is still worried about revenue growth next year despite obesity pill: BMO's Seigerman

Evan Seager is head of healthcare research at Beimo. He's only got a market perform on Novo. He says this is a big win, but sees a challenged road ahead.He's here on set with us. First of all, welcome. >> Thank you for having me.It's great to be here despite the weather. >> Yes. And as you say, despite this having been a total hold on for dear life year for healthcare broadly, but a nice finish.No, I mean, go back to the summer when you had the health insurers, you know, collapsing and all this stuff going ...